Abstract
In Japan, 6 anti-MRSA drugs have been approved. We report here a hemodialysis patient with severe MRSA infection who received a lifesaving combination therapy of daptomycin and linezolid. The patient was a 47-year-old man. He had been undergoing hemodialysis for 13 years. He developed a catheter infection in a nearby hospital and was admitted to our hospital. The patient had septic pulmonary embolism and systemic infection. Blood culture revealed MRSA, and consequently the patient was treated with vancomycin but did not improve. Therefore, iliopsoas muscle abscess drainage was performed and the antimicrobial therapy was changed to a combination of daptomycin and linezolid. Subsequently, the inflammatory response improved, and pneumonia and abscess improved on CT. Thus, daptomycin and linezolid were discontinued. No recurrence occurred thereafter, and the patient was transferred to a rehabilitation clinic after implantation of an artificial vascular prosthesis. Vancomycin is often the first-line therapy for MRSA infection, but it is associated with the problem of poor tissue penetration. In this report, we describe a patient with systemic lesions from MRSA infection. A combination of daptomycin and linezolid was used, and the patient's life was saved. Combination therapy of anti-MRSA drugs can be an effective treatment option for severe MRSA infection.
